Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412342 | 0.80 | GRM2 (0.41) | CNR2KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL410545 | 0.77 | NPC1 (0.47) | CNR2KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL412366 | 0.76 | NPC1 (0.43) | CNR2CNR1 | |
| SCHEMBL412054 | 0.75 | CNR2 (0.43) | CNR2KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL412025 | 0.75 | CNR2 (0.41) | CNR2KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL411538 | 0.74 | ALDH1A1 (0.43) | CNR2KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL9978011 | 0.73 | PTGDR2 (0.46) | CNR2KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL412351 | 0.73 | MEN1 (0.45) | CNR2KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL412341 | 0.73 | NPC1 (0.53) | CNR2KCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL412040 | 0.73 | CNR2 (0.45) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | CNR2 435/4885KCNH2 3316/4885SCN5A 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.